לקסיבה

País: Israel

Idioma: hebreo

Fuente: Ministry of Health

Ingredientes activos:

FOSAMPRENAVIR AS FOSAMPRENAVIR CALCIUM 700 MG

Disponible desde:

GLAXO SMITH KLINE (ISRAEL) LTD

Código ATC:

J05AE07

formulario farmacéutico:

TABLETS

Vía de administración:

PER OS

Fabricado por:

GLAXO WELLCOME SA, SPAIN

Grupo terapéutico:

FOSAMPRENAVIR

indicaciones terapéuticas:

Lexiva is indicated in combination with other antiretroviral agents for the treatment of Human Immunodeficiency Virus (HIV) infection in adults. The following points should be considered when initiating therapy with Lexiva/ritonavir in protease inhibitor - experienced patients: - The protease inhibitor - experienced patient study was not large enough to reach a definitive conclusion that Lexiva/ritonavir and lopinavir/ritonavir are clinically equivalent. - Once - daily administration of Lexiva plus ritonvir is not recommended for proteaseinhibitor-experienced patients.

Fecha de autorización:

2012-01-01